Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACA...
October 08 2020 - 8:32AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced the acceptance and oral presentation details of two sets
of data at the virtual American Academy of Child and Adolescent
Psychiatry (AACAP) 2020 Annual Meeting. The oral presentations will
take place during the “Research Pipeline: New Findings on
Diagnostic and Therapeutics” session. The AACAP annual meeting is
being held virtually from October 12th through October 24th, 2020.
A copy of the slides will be made available on Friday October 23rd
at the time of presentation on the Zynerba corporate website at
http://zynerba.com/publications/.
“We are honored to be invited to provide two oral presentations
at the virtual AACAP annual meeting to further describe the
important responses to Zygel observed in clinical trials in
children and adolescents with Fragile X syndrome (FXS) and autism
spectrum disorder (ASD), respectively, including data reported by
parents and caregivers,” said Joseph Palumbo, MD, FAPA,
MACPsych, Chief Medical Officer of Zynerba. “On behalf of
participating families and investigators, we look forward to
sharing these results with the AACAP scientific community.”
Friday, October 23rd,
2020 from 2:00 to
4:00 PM
EDT
Title: “ZYN002 Cannabidiol Transdermal Gel in Children and
Adolescents With Fragile X Syndrome: Role of Methylation Status as
a Correlate to Disease Severity and as a Prognostic
Biomarker”Session: “Research Pipeline: New Findings on Diagnostic
and Therapeutics”Presentation number: 32.8
Title: “Tolerability and Efficacy of ZYN002 Cannabidiol
(CBD) Transdermal Gel in Children and Adolescents With Autism
Spectrum Disorder: An Open-Label Phase 2 Study [BRIGHT
(ZYN2-CL-030)]”Session: “Research Pipeline: New Findings on
Diagnostic and Therapeutics”Presentation number: 32.7
About Zynerba Pharmaceuticals, Inc.Zynerba
Pharmaceuticals is the leader in pharmaceutically-produced
transdermal cannabinoid therapies for rare and near-rare
neuropsychiatric disorders. We are committed to improving the lives
of patients and their families living with severe, chronic health
conditions including Fragile X syndrome, autism spectrum disorder,
22q11.2 deletion syndrome, and a heterogeneous group of rare and
ultra-rare epilepsies known as developmental and epileptic
encephalopathies. Learn more at www.zynerba.com and follow us on
Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. These and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Zynerba ContactWill Roberts,
VP Investor Relations and Corporate
Communications484.581.7489robertsw@zynerba.com
Media contactMolly DevlinEvoke
KYNE215.928.2199Molly.Devlin@evokegroup.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024